Clovis Oncology, Inc.
Clovis Oncology, Inc. is listed today as Clovis Oncology: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2013 | $192 M | Issued in a merger or acquisition | $50 to $250 million | equity | SEC | |
| May 2009 | $146 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Clovis Oncology, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2013).
SEC Form D · Nov 2013
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Nov 2013
That is all the official record says: Clovis Oncology, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Clovis Oncology, Inc. are on record.
Investors#
14 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Andrew R. Allen | Person | not stated | not stated | Held Series A-1, A-2 and B preferred stock (Form 3, 2011) | SEC Form 3 |
| Domain Parters VII L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| DP VII Associates LP | Fund or asset manager | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| Edward J. McKinley | Person | not stated | not stated | Held Series A-1, A-2 and B preferred stock, director (Form 3, 2011) | SEC Form 3 |
| Erle T. Mast | Person | not stated | not stated | Held Series A-1, A-2 and B preferred stock (Form 3, 2011) | SEC Form 3 |
| Gillian C. IVers-Read | Person | not stated | not stated | Held Series A-1, A-2 and B preferred stock (Form 3, 2011) | SEC Form 3 |
| NEA 13 GP, Ltd | Company | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| NEA Partners 13, Limited Partnership | Fund or asset manager | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| New Enterprise Associates 13 LP | Fund or asset manager | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| Patrick J. Mahaffy | Person | not stated | not stated | Held Series A-1, A-2 and B preferred stock, director (Form 3, 2011) | SEC Form 3 |
| Thorlef Spickschen | Person | not stated | not stated | Held Series A-1, A-2 and B preferred stock, director (Form 3, 2011) | SEC Form 3 |
| Versant Side Fund IV, L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| Versant Venture Capital IV, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
| Versant Ventures IV, LLC | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2011) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 19 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Andrew R. Allen | Executive Vice President of Clinical and Pre-Clinical Development and Chief Medical Officer | Nov 2013 |
| Erle T. Mast | Executive Vice President and Chief Financial Officer | Nov 2013 |
| Gillian C. Ivers-Read | Executive Vice President of Technical Operations and Chief Regulatory Officer | Nov 2013 |
| Patrick J. Mahaffy | President, Chief Executive Officer and Director | Nov 2013 |
| Steven L. Hoerter | Senior Vice President, Commercial | Nov 2013 |
| Brian G. Atwood | Director | Nov 2013 |
| Edward J. McKinley | Director | Nov 2013 |
| Ginger L. Graham | Director | Nov 2013 |
| James C. Blair | Director | Nov 2013 |
| Keith L. Flaherty | Director | Nov 2013 |
| M. James Barret | Director | Nov 2013 |
| Patrick J. Mahaffy | President, Chief Executive Officer and Director | Nov 2013 |
| Paul C. Klingenstein | Director | Nov 2013 |
| Thorlef J. Spickschen | Director | Nov 2013 |
About
Small pharmaceutical company.